Eli Lilly and Company
2,6-DIAMINO PYRIDINE COMPOUNDS
Last updated:
Abstract:
The present invention provides a compound of Formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
Status:
Application
Type:
Utility
Filling date:
29 Aug 2019
Issue date:
5 Mar 2020